Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study-Reference-Cited by-同舟云学术

Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study

Published:2019-08-10 Issue:9 Volume:110 Page:2924-2932
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Iida Shinsuke¹^ORCID,Watanabe Takashi²,Matsumoto Morio³,Suzuki Kenshi⁴,Sunami Kazutaka⁵,Ishida Tadao⁶^ORCID,Ando Kiyoshi⁷,Chou Takaaki⁸,Ozaki Shuji⁹,Taniwaki Masafumi¹⁰,Uike Naokuni¹¹,Shibayama Hirohiko¹²,Hatake Kiyohiko¹³,Izutsu Koji¹⁴,Ishikawa Takayuki¹⁵,Shumiya Yoshihisa¹⁶,Tobinai Kensei²

Affiliation:

1. Department of Hematology and Oncology Nagoya City University Graduate School of Medical Sciences Nagoya Japan

2. Department of Hematology National Cancer Center Hospital Tokyo Japan

3. Department of Hematology National Hospital Organization Shibukawa Medical Center Shibukawa Japan

4. Department of Hematology Japanese Red Cross Medical Center Tokyo Japan

5. Department of Hematology National Hospital Organization Okayama Medical Center Okayama Japan

6. Department of Gastroenterology, Rheumatology and Clinical Immunology Sapporo Medical University School of Medicine Sapporo Japan

7. Department of Hematology and Oncology Tokai University School of Medicine Isehara Japan

8. Department of Internal Medicine Niigata Cancer Center Hospital Niigata Japan

9. Department of Hematology Tokushima Prefectural Central Hospital Tokushima Japan

10. Division of Hematology and Oncology Graduate School of Medical Science Kyoto Prefectural University of Medicine Kyoto Japan

11. Department of Hematology National Hospital Organization Kyushu Cancer Center Fukuoka Japan

12. Department of Hematology and Oncology Osaka University Graduate School of Medicine Suita Japan

13. Department of Hematology and Oncology The Cancer Institute Hospital of Japanese Foundation for Cancer Research Tokyo Japan

14. Department of Hematology Toranomon Hospital Tokyo Japan

15. Department of Hematology Kobe City Medical Center General Hospital Kobe Japan

16. Department of Oncology Clinical Development Planning Ono Pharmaceutical Co., Ltd Osaka Japan

Funder

Ono Pharmaceutical Co., Ltd

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.14139

Reference18 articles.

1. HowladerN NooneAM KrapchoM et al.SEER Cancer Statistics Review 1975–2014.Bethesda MD:National Cancer Institute.https://seer.cancer.gov/csr/1975_2014/ based on November 2016 SEER data submission posted to the SEER web site April 2017. Accessed February 20 2019.

2. Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project

3. Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines

4. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Carfilzomib, thalidomide, and dexamethasone is safe and effective in relapsed and/or refractory multiple myeloma: final report of the single arm, multicenter phase II ALLG MM018/AMN002 study.;Haematologica;2024-01-18

2. Cardiovascular Toxicity of Carfilzomib: The Real-World Evidence Based on the Adverse Event Reporting System Database of the FDA, the United States;Frontiers in Cardiovascular Medicine;2021-09-27

3. Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial;International Journal of Hematology;2021-08-19

4. Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (A.R.R.O.W.) and comparison with ENDEAVOR;International Journal of Hematology;2020-10-10

5. Efficacy of Panobinostat for the Treatment of Multiple Myeloma;Journal of Oncology;2020-01-13